These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 27247223)

  • 1. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.
    Kerr KF; Brown MD; Zhu K; Janes H
    J Clin Oncol; 2016 Jul; 34(21):2534-40. PubMed ID: 27247223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Clinical Impact of Risk Models for Opting Out of Treatment.
    Kerr KF; Brown MD; Marsh TL; Janes H
    Med Decis Making; 2019 Feb; 39(2):86-90. PubMed ID: 30649998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer.
    Wong LM; Neal DE; Finelli A; Davis S; Bonner C; Kapoor J; Trachtenberg J; Thomas B; Hovens CM; Costello AJ; Corcoran NM
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):137-43. PubMed ID: 25667108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Framework for Treatment Decision Making at Prostate Cancer Recurrence.
    Lange JM; Trock BJ; Gulati R; Etzioni R
    Med Decis Making; 2017 Nov; 37(8):905-913. PubMed ID: 28564551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
    Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
    Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives.
    Steyerberg EW; Vedder MM; Leening MJ; Postmus D; D'Agostino RB; Van Calster B; Pencina MJ
    Biom J; 2015 Jul; 57(4):556-70. PubMed ID: 25042996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
    Reed SD; Stewart SB; Scales CD; Moul JW
    Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation.
    Hansen J; Becker A; Kluth LA; Rink M; Steuber T; Zacharias M; Briganti A; Fisch M; Graefen M; Chun FK
    Urol Oncol; 2015 Sep; 33(9):384.e1-8. PubMed ID: 26122714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the weighted area under the net benefit curve for decision curve analysis.
    Talluri R; Shete S
    BMC Med Inform Decis Mak; 2016 Jul; 16():94. PubMed ID: 27431531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
    Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
    Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
    Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
    BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.
    Vickers AJ; Cronin AM; Elkin EB; Gonen M
    BMC Med Inform Decis Mak; 2008 Nov; 8():53. PubMed ID: 19036144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
    Fleming C; Wasson JH; Albertsen PC; Barry MJ; Wennberg JE
    JAMA; 1993 May; 269(20):2650-8. PubMed ID: 8487449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.